These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10097251)

  • 1. Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults.
    Bisi G; Podio V; Valetto MR; Broglio F; Bertuccio G; DEl Rio G; Boghen MF; Berti F; Muller EE; Ghigo E
    Eur J Endocrinol; 1999 Apr; 140(4):322-7. PubMed ID: 10097251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human IGF-I does not modify the ACTH and cortisol responses to hCRH and hexarelin, a peptidyl GH secretagogue, in humans.
    Gianotti L; Ramunni J; Lanfranco F; Maccagno B; Giordano R; Broglio F; Maccario M; Muller EE; Ghigo E; Arvat E
    J Endocrinol Invest; 2001 Feb; 24(2):67-71. PubMed ID: 11263473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism.
    Mauras N; Martinez V; Rini A; Guevara-Aguirre J
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3036-42. PubMed ID: 10999782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.
    Carroll PV; Umpleby M; Alexander EL; Egel VA; Callison KV; Sönksen PH; Russell-Jones DL
    Clin Endocrinol (Oxf); 1998 Dec; 49(6):739-46. PubMed ID: 10209561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa.
    Gianotti L; Pincelli AI; Scacchi M; Rolla M; Bellitti D; Arvat E; Lanfranco F; Torsello A; Ghigo E; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2805-9. PubMed ID: 10946886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I.
    Chapman IM; Hartman ML; Pieper KS; Skiles EH; Pezzoli SS; Hintz RL; Thorner MO
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2836-42. PubMed ID: 9709956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
    Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus.
    Acerini CL; Harris DA; Matyka KA; Watts AP; Umpleby AM; Russell-Jones DL; Dunger DB
    Metabolism; 1998 Dec; 47(12):1481-9. PubMed ID: 9867078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus.
    Crowne EC; Samra JS; Cheetham T; Watts A; Holly JM; Dunger DB
    Metabolism; 1998 Jan; 47(1):31-8. PubMed ID: 9440474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
    Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of recombinant IGF-I on anterior pituitary function in healthy volunteers.
    Trainer PJ; Holly J; Medbak S; Rees LH; Besser GM
    Clin Endocrinol (Oxf); 1994 Dec; 41(6):801-7. PubMed ID: 7889617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback.
    Chapman IM; Hartman ML; Pezzoli SS; Harrell FE; Hintz RL; Alberti KG; Thorner MO
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2996-3004. PubMed ID: 9284733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of acute elevation of IGF-I on circulating GH, TSH, insulin, IGF-II and IGFBP-3 levels in non-endocrine short stature (NESS).
    Hanew K; Tanaka A
    J Endocrinol Invest; 2001 Jan; 24(1):1-7. PubMed ID: 11227726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired cardiac performance in elderly patients with growth hormone deficiency.
    Colao A; Cuocolo A; Di Somma C; Cerbone G; Della Morte AM; Nicolai E; Lucci R; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1999 Nov; 84(11):3950-5. PubMed ID: 10566633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans.
    Bisi G; Podio V; Valetto MR; Broglio F; Bertuccio G; Del Rio G; Arvat E; Boghen MF; Deghenghi R; Muccioli G; Ong H; Ghigo E
    J Endocrinol Invest; 1999 Apr; 22(4):266-72. PubMed ID: 10342360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.